Serum free light chains: diagnostic and prognostic value in multiple myeloma by Sthaneshwar, Pavai et al.
Clin Chem Lab Med 2009;47(9):1101–1107  2009 by Walter de Gruyter • Berlin • New York. DOI 10.1515/CCLM.2009.260 2009/228
Article in press - uncorrected proof
Serum free light chains: diagnostic and prognostic value
in multiple myeloma
Pavai Sthaneshwar*, Veerasekaran Nadarajan,
Jayaranee A.S. Maniam, Nani Nordin and
Gan Gin Gin
Department of Pathology, University of Malaya,
Kuala Lumpur, Malaya
Abstract
Background: Measurement of serum free light chains
(FLCs) has recently become available for the diagno-
sis and monitoring of patients with plasma cell dys-
crasias. The aim of this study was to investigate the
performance of the serum FLC assay as a tumour
marker by comparing FLC concentrations with serum
protein electrophoresis (PE) results in the diagnosis
of multiple myeloma (MM). In addition, we also eval-
uated the prognostic value of the baseline serum FLC
ratio in patients with MM.
Methods: We measured FLC concentrations and cal-
culated the kappa/lambda (k/l) FLC ratios for three
groups (control, polyclonal gammopathy and MM).
Results: The FLC ratio at a cut-off threshold of 2.0
showed higher sensitivity and specificity compared
with serum electrophoresis for the diagnosis of MM.
We used the median FLC ratio of )57.5 and -0.04
for k and l secretors, respectively, for assessing sur-
vival. Survival was 30 months in patients with the
k/l ratio of )57.5 and -0.04 compared to 47 months
in patients with the ratio -57.5 and )0.04, indicating
that more abnormal serum FLC ratios are associated
with poorer survival (p-0.011).
Conclusions: Despite the limitations of the assay, the
results of our study indicate that the FLC assay in
combination with serum PE has an increased sensi-
tivity in the diagnosis of MM. Also, baseline measure-
ment of the k/l ratio provides prognostic information
in these same patients.
Clin Chem Lab Med 2009;47:1101–7.
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Introduction
Monoclonal gammopathies are a group of disorders
characterised by clonal expansion of B cells that
usually secrete intact monoclonal immuoglobulins,
monoclonal free light chains (FLCs) or both. Theymay
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be present as a spectrum of diseases that include
multiple myeloma (MM), Waldenstrom’s macroglo-
bulinaemia, asymptomatic myeloma, non-secretory
myeloma, AL-amyloidosis, light chain deposition dis-
ease and monoclonal gammopathy of undetermined
significance (MGUS) (1). Until recently, the recom-
mended laboratory algorithm for patients suspected
of having MM, primary amyloid (AL), and related dis-
orders included serum or urine protein electrophore-
sis (PE) and immunofixation electrophoresis (IFE) to
optimise detection of monoclonal gammopathies (2).
Quantitation of monoclonal protein (M-protein) by PE
is recommended as a tumour marker in patients with
monoclonal gammopathy (3, 4). However, PE is a
semiquantitative method for detection of M proteins,
and may be misinterpreted as a negative result due
to lack of sensitivity, or the masking effect from other
proteins when the M-protein is not present in the g
fraction. The accuracy of urine PE has been ques-
tioned in patients with proteinuria (5). Moreover, PE
and IFE have limited use in the identification of
patients with light chain MM (LCMM), non-secretory
MM and AL amyloidosis where the M-protein may not
be present in sufficient concentrations for detection.
In order to diagnose and monitor these patients, an
alternative assay has been developed to identify, cha-
racterise and quantitate serum FLCs. The only com-
mercially available quantitative assay for FLCs was
introduced in 2001 (FREELITE, The Binding Site Ltd,
Birmingham, UK). This immunoassay measures very
low concentrations of FLC in serum, with virtually no
cross reactivity with light chains contained within
intact immunoglobulins (6). This assay is not capable
of distinguishing monoclonal from polyclonal FLCs,
but the use of the kappa to lambda (k/l) ratio enables
the identification of imbalances in light chain produc-
tion. Abnormal k and l FLC ratios may be due to
immune suppression, immune stimulation, reduced
renal clearance or monoclonal lymphoplasmacytic
proliferative disorders. Sera from patients with either
polyclonal hypergammaglobulinaemia or renal
impairment often have increased k FLC and l FLC, but
in these cases the k/l FLC ratio remains normal. It is
presumed that abnormal k/l FLC ratios only result
from a clonal B-lymphoid or plasma cell proliferative
disorder, and is interpreted as evidence of free mono-
clonal light chains in the serum. Recently, Snozek et
al. (7) have described that the concentration of serum
FLCs at initial diagnosis is an important predictor of
prognosis in myeloma, and can be incorporated into
International Staging System (ISS) for improved risk
stratification.
The goal of this study was to investigate the per-
formance of the serum FLC assay as a tumour marker
by comparing FLC concentrations with serum PE for
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Table 1 Sensitivity, specificity, PPV and NPV of the k/l ratio at different cut-off thresholds, and serum protein electrophoresis.
Method (cut-off value) Sensitivity, % Specificity, % PPV, % NPV, %
k/l (0.5–1.2) 96.6 93.0 93.4 96.5
k/l (0.26–1.65) 96.6 96.6 96.6 96.6
k/l (0.5–2.0) 96.6 100 100 96.8
Serum PE 86.4 100 100 88.2
PPV, positive predictive value; NPV, negative predictive value; serum PE, serum protein electrophoresis.
the diagnosis of MM. In addition, we also evaluated
the prognostic value of baseline serum FLC ratios in
these same patients.
Patients and methods
The study group comprised 59 patients who had been diag-
nosed with MM from 1999 to 2008, and 30 patients whowere
noted to have polyclonal gammopathy due either to infec-
tion or inflammation. Archived serum samples from blood
collected at the time of initial diagnosis were available for
measurement of serum FLCs. The reference interval for
serum FLC was established using 30 blood samples collected
from healthy blood donors. The clinical diagnosis of MM
was based on findings of serum or urine PE and IFE, plasma
cell content of bone marrow aspirates or trephine biopsies,
together with the clinical features of MM, including lytic
bone lesions or fractures. Information regarding patient
demographics, clinical presentations and indicators of dis-
ease activity, such as serum calcium, serum albumin, hae-
moglobin, platelet count, M-protein concentrations, plasma
cell infiltration, C-reactive protein (CRP) concentrations,
serum b2-microglobulin (b2M) and presence of bony lytic
lesions recorded at the time of diagnosis, were retrieved
from the medical records and the laboratory information
system. Serum FLC concentrations were measured using a
latex-enhanced immunonephelometry method (The Binding
Site, Birmingham, UK) performed using the Beckman Coul-
ter IMMAGE800 analyser (Beckman Coulter, Brea, CA,
USA).
Statistical analysis
Means, standard deviations (SDs) and reference intervals
(mean"2 SD) were calculated for k, l and the k/l ratio.
One-way ANOVA was used to compare the mean k/l ratio
in normal, polyclonal and MM patients.
Sensitivity, specificity, positive predictive value (PPV) and
negative predictive value (NPV) were calculated for the k/l
ratio using different cut-off thresholds and for the results of
serum PE (Table 1).
Survival was defined as the time from initial diagnosis to
death or the last follow-up and was calculated by themethod
of Kaplan and Meier (8). The survival curves were compared
using the log-rank test. The Cox proportional hazards regres-
sion model was used to analyse univariately the influence of
prognostic factors on survival. Statistically significant factors
were further tested in multivariate analysis with stepwise
forward selection. p-Values-0.05 were considered to be sig-
nificant. The relationship between abnormal k/l ratio and the
other disease related parameters was assessed using the x2-
test. Statistical analysis was performed using SPSS for
Windows version 11.0 (SPSS Inc., Chicago, IL, USA).
Results
The reference range for the serum k, l and k/l ratio
calculated from 30 healthy donors was found to be
4.42–17.7, 7.63–18.23 and 0.50–1.20 mg/L, respective-
ly (mean"2 SD). The reference intervals recommend-
ed by the manufacturer for k and l when using this
platform are 3.3–19.4 mg/L and 5.7–26.3 mg/L,
respectively. The mean (median) serum k, l and k/l
ratio in the group with polyclonal gammopathy were
69.47 (52.8), 86.85 (54.1) and 0.89 (0.81) mg/L, respec-
tively. The mean k and l values were significantly
increased compared to the controls (p-0.05), but no
significant difference was noted in the k/l ratio
(ps0.73) between controls and patients with polyclo-
nal gammopathy.
Fifty-three patients with MM (90%) had intact
immunoglobulin MM (IIMM). Based on IFE results, 44
(83%) of them were identified to have the IgG isotype,
eight (15%) with IgA and one (2%) with IgM. k Light
chain restriction was observed in 30 (57%) patients
and l light chain restriction in 23 (43%). The remain-
ing six patients were diagnosed as light chain MM
(LCMM). Three of the six LCMM patients (10%) were
noted to be k secretors, and the other three were l
secretors. The mean (median) k, l concentrations in
59 patients with MM were 819.98 (140.75) mg/L and
841.85 (14.3) mg/L, respectively. These values were
significantly increased when compared to those in the
control group; ps0.003, 0.035. The mean (median)
k/l ratio for k secretors and l secretors were 135.9
(57.5) and 0.24 (0.04), respectively. The k/l ratio in
MM was significantly abnormal compared to that of
controls (ps0.005), and the group with polyclonal
gammopathy (ps0.008). The distributions of k and l
FLC in the control group, polyclonal group and
patients with MM are shown in the scatter plot (Figure
1). The distribution of the k/l ratio in the control
group, polyclonal gammopathy group, and k-MM and
l-MM groups are shown in the box plot (Figure 2).
Fourteen of the patients with MM succumbed to their
disease. In nine patients, there was no follow-up after
a period of time.
Of the 59 patients with MM, 57 had increased serum
FLC concentrations and abnormal k/l ratios according
to the type of light chain restrictions. Two patients
had a normal k/l ratio and both of these patients had
IgG-l MM. In one of them, serum k and l concentra-
tions were normal, the other patient showed k and l
concentrations that were increased, accounting for
the normal k/l ratio. In the patients with polyclonal
gammopathy, higher serum FLC concentrations were
observed. However, the k/l ratio was within the val-
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Figure 1 Distributions of k and l FLC in normal, multiple
myeloma and polyclonal gammopathy group.
Figure 2 Distribution of k/l ratio in control, polyclonal
gammoapthy, multiple myeloma with k- and l restriction.
ues obtained for our reference population in all except
four in whom the k/l ratio was slightly increased
(k/l ratio )1.2 and -2). When a cut-off threshold for
the k/l ratio of 2.0 was used, it showed better sensi-
tivity, specificity, PPV and NPV (Table 1) when com-
pared with the reference value for the k/l ratio of
0.2–1.65, and when compared with serum PE.
In eight patients with MM, the M-protein was not
detected in the g region by serum PE. However, the
PE showed abnormally elevated b and a2 globulins
in three and one patient, respectively. These four
patients were diagnosed with intact IgA MM by serum
IFE. The other four patients had LCMM. In two of
these patients, serum PE showed no abnormalities,
whereas the other two were noted to have hypogam-
maglobulinaemia. However, the M-protein was iden-
tified in PE and IFE of urine. All eight patients had
increased serum FLC concentrations and an abnormal
k/l ratio.
Survival analysis and prognostic significance
of serum FLC and other variables
The median survival time for the patients with MM
patients was noted to be 43 months. Univariate anal-
ysis of the parameters using Cox proportional hazards
regression showed that six out of the ten variables
analysed were associated significantly with survival.
These variables included albumin, calcium, creati-
nine, the serum FLC ratio, ISS, and b2M (Table 2 and
Figure 3). A median FLC ratio )57.5 and -0.04 for k
and l secretors, respectively, was used for assessing
prognosis. In the multivariate analysis, the serum FLC
ratio (k/l and l/k ratio), serum b2M and serum calci-
um concentrations were found to have independent
prognostic predictive value for survival. p-Values
were 0.011, 0.006 and 0.022, respectively.
Correlations with parameters of disease activity
(Table 3)
The FLC ratio correlated with creatinine, haemoglo-
bin, calcium, b2M, Durie-Salmon staging (DSS) and
ISS (p-0.05). No correlation was noted with age,
gender, and albumin (p)0.05).
Discussion
Serum PE is the most common test in use for detect-
ing monoclonal immunoglobulins, with a sensitivity
that is between 500 mg/L and 2000 mg/L (9). The wide
range of sensitivity can be explained by the different
migration patterns of M-proteins. In the majority of
cases, the monoclonal component migrates in the g
globulin region and is easier to detect. However,
occasionally the M-spike can be missed if it is masked
by proteins within the b and a globulin region. Immu-
nofixation is a more sensitive technique and can
detect between 100 mg/L and 150 mg/L of M-protein
(6). A new commercially available automated immu-
noassay enables quantifitation of serum k and l FLCs.
The ability of the FLC assay to identify most patients
with LCMM suggests that analysis of urine may rarely
be needed for diagnosis of these patients (3). The
serum FLC assay has also been shown to be useful
for the diagnosis and monitoring of patients with
non-secretory myeloma (10). In our study, 96.6% (57/
59) of patients with MM had increased serum FLC
concentrations and an abnormal k/l ratio. The light
chains were increased according to the clonal type. In
two patients, the serum FLC ratio was within the ref-
erence interval, although serum PE showed the pres-
ence of M-protein. It has been reported that in 10% of
IIMM, the k/l ratio can be normal (11, 12). However,
in our study, serum PE was not helpful in diagnosing
MM in eight patients (10%), and the M-protein was
detected either by IFE or urine PE. Four of these
patients had an M-band migrating within the b or a2
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Table 2 Cox model and univariate analysis of patients with multiple myeloma.
Parameters Median survival Number, n p-Value
rate, months
Age, years
-65 46 34 0.22
)65 42 25
Sex
Male 47 28 0.69
Female 42 31
Hb, g/L
G100 43 29 0.38
-100 35 30
Serum FLC ratio
-57.5 or )0.04 47 28 0.04
)57.5 or -0.04 30 31
Calcium, mmol/L
-2.5 47 36 0.002
G2.5 20 23
Measured albumin, g/L
-35 35 42 0.02
G35 72 17
Creatinine, mmol/L
G115 22 38 0.045
-115 43 21
b2M, mg/L
-5.5 47 36 0.013
)5.5 30 23
DS staging






1 No event 5 0.045
2 42 31
3 30 23
Hb, haemoglobin; FLC, free light chain; b2M, b2-microglobulin; DS, Durie-Salmon; IS, International Staging.
Figure 3 Survival functions.
region, and the remaining four patients had LCMM.
In all these patients, the k/l ratio was abnormal.
Serum FLC assays are more sensitive than PE in con-
ditions, such as LCMM and MM, where the M-spike
can be masked by other proteins.
Increased concentration of FLC can occur not only
in MM, but also in inflammation or infection where
there is an increased synthesis (4). In addition,
patients with renal impairment can retain FLCs for a
longer time (6, 13). We noted increased serum FLC
concentrations in patients with polyclonal gammo-
pathy, but their k/l ratios were usually normal. In
three patients, the ratio was slightly increased but
-2.0. Abadie et al. (14) observed a mildly increased
k/l ratio up to 3.1 with increased serum creatinine
and/or polyclonal hypergammaglobulinaemia. Hence,
they recommended a suitable reference interval to be
used in interpreting results in these patients. Using a
cut-off threshold of 2.0 for the FLC ratio, 100% PPV
and 96.8% NPV was noted, enabling us to differentiate
polyclonal gammopathy from MM. Similar findings
have been reported by Kang et al. (15). The present
study shows higher sensitivity when a cut-off thresh-
old of 2.0 for the k/l ratio was used, compared to
serum PE (96.6% vs. 86.4%) in detecting MM. This
finding is in agreement with that of other studies (15,
16). The sensitivity was 100% when both assays were
used. Therefore, if a diagnosis of MM is suspected,
optimum laboratory practice should be to screen sera
using both electrophoresis and the FLC assay.
The outcome for patients with MM is highly varia-
ble. With the use of conventional chemotherapy, the
median survival of patients with MM has been
;3 years, and the proportion of long-term survivors
is disappointingly small. Since the first formal publi-
cation 40 years ago by Carbone et al. (17), several
prognostic factors that identify groups of patients
with significantly different survival probabilities have
Sthaneshwar et al.: Serum free light chains in multiple myeloma 1105
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Table 3 Comparison of patient demographics according to baseline FLC ratios.
Parameters FLC ratio FLC ratio p-Value
-57.5 or )0.04 )57.5 or -0.04 x2
(ns28) (ns31)
Age, years
-65 15 19 )0.05
)65 13 12
Sex
Male 15 13 )0.05
Female 13 18
Hb, g/L
G100 21 8 -0.0001
-100 7 23
Calcium, mmol/L
-2.5 21 15 -0.05
G2.5 7 16
Measured albumin, g/L
-35 18 7 )0.05
G35 10 24
Creatinine, mmol/L
-115 23 15 -0.001
G115 5 16
b2M, mg/L
-5.5 22 14 -0.001
G5.5 6 17
DS staging
1 and 2 12 6
3 16 25 -0.05
IS staging
1 and 2 22 14 -0.01
3 6 17
Hb, hemoglobin; FLC, free light chain; b2M, b2-microglobulin; DS, Durie-Salmon; IS, International Staging.
been identified. In 1975, the DSS system (18) was
introduced and is still widely used. In the 1980s, b2M
emerged as a simple reliable predictor of survival.
Subsequently, other prognostic factors were intro-
duced, including serum CRP, albumin, the plasma cell
labelling index, cell cycle analysis, creatinine clear-
ance and deletion of chromosome 13 (19, 20). In our
study, univariantly significant baseline factors asso-
ciated with decreased survival were albumin -35
g/L, calcium G2.5 mmol/L, creatinine G115 mmol/L, a
serum FLC ratio )57.5 and -0.04, higher Internation-
al Staging, and b2M )5.5 mg/L (Table 2). Among
these baseline variables, the serum FLC ratio, serum
b2M and serum calcium retained independent prog-
nostic significance.
Several biochemical markers are linked to disease
activity, and the most important of them is b2M con-
centrations. b2M is part of the major histocompatibil-
ity complex class I molecule on the cell surface of
nucleated cells, and is regarded as the most important
prognostic factor in MM. The ISS uses serum b2M
concentrations for staging of MM. b2M concentra-
tions increase as a result of both tumour burden and
deterioration of renal function. Several threshold
values for b2M (3–6 mg/dL) have been used to dis-
criminate prognostic subgroups (21, 22). We used a
cut-off threshold of 5.5 mg/dL. The higher the b2M
value, the shorter the survival (21, 22).
The DSS system categorises patients into 1 of 3
categories (stage I, II, or III) based on haemoglobin
concentrations, serum calcium concentrations, the
production rate of M-protein, and the number of
osteolytic lesions. Hypercalcaemia remains the most
frequent metabolic complication in patients with
myeloma, and excessive osteolysis plays a major
contributory role in its pathogenesis. In the study by
Abildgaard et al. (23), serum calcium showed the
highest prognostic significance using multivariate
analysis. Higher serum calcium concentrations were
also associated with poorer outcome of patients in
our study, and multivariate analysis showed calcium
to be an independent prognostic factor (p-0.02).
Abnormal baseline FLC ratios correlated with creati-
nine, calcium, DSS, b2M and ISS staging, indicating
more aggressive disease and higher tumour burden.
Similar findings have been reported by van Rhee
et al. (24).
Recently, Kyrtsonis et al. (25) described the use of
serum FLC concentrations for predicting prognosis,
independently of the ISS, in a relatively small group
of patients with MM. A study by van Rhee et al. (24)
in the same year confirmed that the baseline FLC ratio
was predictive of survival within the first 2 years fol-
lowing diagnosis. Snozek et al. (7) suggested that the
serum FLC ratio at initial diagnosis is an important
predictor of prognosis in myeloma, and can be incor-
porated into the ISS for improved risk stratification.
In their study, they observed that median survival was
lower in patients with FLC ratios of -0.03 and )32.
We used the median FLC ratio of )57.5 and -0.04
for k and l secretors, respectively, for assessing sur-
vival. The median FLC ratio used in the study is dif-
ferent from that reported by Snozek et al. (7), possibly
due to the smaller number of MM patients in our
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study; 23 (39%) of which were in stage 3. The different
value used could also be attributed to different
analysers used in the studies. According to Tate et al.
(13), discordant results arising from instruments
include differences in the analyser performance, or
analytical imprecision on the calculation of the FLC
ratio. The survival was 30 months in patients with the
k/l ratio of )57.5 and -0.04, compared to 47 months
in patients with the ratio -57.5 and )0.04. This indi-
cates that higher serum FLC ratios are associated
with poorer survival (p-0.011). Our study also sup-
ports the findings of previous investigators who
found that the serum FLC ratio is an independent
prognostic variable in MM. In their recent guidelines
for serum-FLC analysis in MM and related disorders,
the International Myeloma Working Group (26) has
recommended three major indications for the FLC
measurement. First, in the context of screening, the
serum FLC assay in combination with serum PE and
immunofixation yields high sensitivity. Second, the
baseline FLC measurement is of major prognostic val-
ue in virtually every plasma cell disorder (PCD). Third,
the FLC assay allows for quantitative monitoring of
patients with oligosecretory PCD.
FLC assays do have some drawbacks. No interna-
tional standard exists for FLCs. Serum FLC concentra-
tions, by themselves cannot be used to diagnose MM.
There is a need for complementary IFE to be per-
formed to confirm the clonality. The FLC ratio can also
be normal in IIMM. Tate et al. (13) reported that the
inaccuracies in the assay could be attributable to
(i) differences in the immunoreactivity of monoclonal
FLCs compared to the polyclonal calibrator used for
calibration and (ii) over or under estimation of FLC
due to polymerisation of monoclonal FLCs. Also, they
have reported that the analytical performance and
FLC values differed between instruments and meth-
odologies. Despite these limitations, the results of our
study indicate that the FLC assay in combination with
serum PE has an increased sensitivity in the diagnosis
of MM, and baseline measurement of the k/l ratio
provides prognostic information in these patients.
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